China Medical System Holdings Limited is a pharmaceutical company focused on the identification, development, and full lifecycle management of differentiated specialty medicines. The company operates through a dual-track model of independent and collaborative research and development, with a core capability in creating markets and brands from scratch. Its therapeutic areas include cardiology, nephrology, metabolism, central nervous system, gastroenterology, ophthalmology, and dermatology. Key products include the TYK2 inhibitor CMS-D001 for systemic lupus erythematosus, the rabies bispecific antibody Jin Su Xi, and the biologic Bai Lu Tuo for atopic dermatitis. The company serves markets in China and emerging regions in Southeast Asia and the Middle East. It also engages in industrial investment, acquiring equity stakes in targets to co-develop products and reinvest returns into research and development.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage cms.net.cn
Sector Healthcare IR page web.cms.net.cn/zh/home
Tags
specialty pharmaceuticals, cardiology, nephrology, metabolism, central nervous system, gastroenterology, ophthalmology, dermatology, tyk2 inhibitors, bispecific antibodies, biologics, systemic lupus erythematosus, CMS-D001, Jin Su Xi, Bai Lu Tuo
Press page web.cms.net.cn/en/news

Metrics

Valuation  
Market cap HK$ 23.21B
Market cap (USD) $ 2.958B
P/E 13.81
PEG —
P/BV —
P/S 6.73
P/OCF 26.00
P/FCF —
Dividend yield 3.6%
Turnover / mcap 0.13%
Returns  
ROE —
ROI 508.2%
ROIC 508.2%
Profit margin 18.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -23.0%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 6.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 CNY FY 2024 CNY FY 2023 CNY FY 2022 CNY FY 2021 CNY FY 2020 CNY FY 2019 CNY FY 2018 CNY FY 2017 CNY FY 2016 CNY FY 2015 CNY FY 2014 CNY FY 2013 USD FY 2012 USD FY 2011 USD FY 2010 USD
Revenue 8.212B 7.469B 8.013B 9.15B 8.337B 6.946B 6.074B 5.433B 5.349B 4.901B 3.553B 2.945B 363.256M 281.866M 210.393M 132.177M
Net profit 1.489B 1.62B 2.401B 3.259B 3.017B 2.53B 1.961B 1.85B 1.675B 1.376B 995.935M 1.046B 102.825M 85.039M 62.276M 30.587M

Figure FY 2025 CNY FY 2024 CNY FY 2023 CNY FY 2022 CNY FY 2021 CNY FY 2020 CNY FY 2019 CNY FY 2018 CNY FY 2017 CNY FY 2016 CNY FY 2015 CNY FY 2014 CNY FY 2013 USD FY 2012 USD FY 2011 USD FY 2010 USD
Share price 12.35 7.45 0.74 0.07 7.14 7.67 0.15 5.96 0.38 — — — — — — —
Price performance 12m 0.7 9.14 8.76 -0.99 0 49.52 -0.98 14.28 — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

NDA of Ruxolitinib Phosphate Cream Lumirix Approved in Singapore Bull 3 Bear 0 Clinical/regulatory

Prompts

China Medical System Holdings Limited (ticker 867), listed in Hong Kong.

ETFs Holding China Medical System Holdings Limited

ETF Weight in ETF Shares Market value As of
ADIV 2.27% 926,000 $ 1.214M Jun 30, 2026
RFEM 0.30% 155,566 $ 236.451K Jul 31, 2026
AVEE 0.16% 169,000 $ 212.831K Nov 16, 2026
AVEM 0.06% 11,754,000 $ 14.802M Nov 16, 2026
AVSE 0.05% 86,000 $ 108.304K Nov 16, 2026
DFSE 0.05% 217,000 $ 285.75K Nov 12, 2026
DFEV 0.03% 521,000 $ 686.064K Nov 12, 2026
DFEM 0.03% 1,744,000 $ 2.297M Nov 12, 2026
DFAE 0.01% 967,000 $ 1.273M Nov 12, 2026
DFAX 0.01% 790,000 $ 1.04M Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
867 canonical Common share — HK hkex 9.54 HKD 2026-11-19
8A8 Common share — SG sgx 1.71 SGD 2026-11-19